Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix, the DTaP Mixed Vaccine.

Trial Profile

Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix, the DTaP Mixed Vaccine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Aug 2009 Actual patient number (1258) added as reported by ClinicalTrials.gov.
    • 28 May 2009 Actual end date changed from Apr 2008 to Jul 2008 as reported by ClinicalTrials.gov.
    • 21 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top